Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
Status:
Terminated
Trial end date:
2020-01-16
Target enrollment:
Participant gender:
Summary
The standard therapy of glioblastoma (GBM) consists of gross total resection followed by
focal irradiation to the tumor bed with concomitant and adjuvant temozolomide (TMZ). The
association of valproic acid and TMZ during radiotherapy improves survival of GBM.
Preclinical studies suggested that doxorubicin had a strong antineoplastic activity against
human gliomas. Moreover, some studies showed that the continuous infusion of anthracyclines
in patients with solid tumor ensured a better safety profile compared with bolus
administration.
Based on these findings, the purpose of this study is to evaluate safety and efficacy of
prolonged administration of doxorubicin in combination with radiotherapy, temozolomide and
valproic acid in pediatric and adult patients with newly diagnosed GBM and diffuse intrinsic
pontine glioma (DIPG).